BioNTech (BNTX) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed BioNTech (BNTX) over the past year, gaining 6.2% versus a loss of 15.3%. Over five years, NBIX leads with a +73.1% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $15.24 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | NBIX |
|---|---|---|
| Share price | $80.96 | $150.57 |
| Market cap | $20.07B | $15.24B |
| 1-day change | -0.52% | -3.84% |
| YTD return | -14.96% | +6.16% |
| 1-year return | -15.30% | +6.16% |
| 5-year return | -76.74% | +73.11% |
| P/E ratio (TTM) | — | 22.34 |
| Forward P/E | — | 12.24 |
| EPS (TTM) | $-6.83 | $6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | — | 16.73% |
| 52-week high | $124.00 | $186.12 |
| 52-week low | $79.52 | $122.14 |
| Distance from 52-week high | -34.71% | -19.10% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.51% | +38.50% |
| Average volume | 1.08M | 1.34M |
| Shares outstanding | 247.93M | 101.22M |
| Employees | 7,807 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBIX has outperformed BNTX by 21.5 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
BNTX vs NBIX FAQ
Which is bigger, BioNTech or Neurocrine Biosciences?
BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $15.24B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, BNTX or NBIX?
NBIX returned +6.16% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.